United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News X-Rx announces FDA acceptance of IND for X-165, a potential treatment for Idiopathic Pulmonary Fibrosis US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic… bypharmanewsdailyJanuary 26, 2019